Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. It focuses on patients with gastroesophageal reflux disease, also known as chronic heartburn, acid reflux or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. The company's lead products include EsoGuard, a laboratory developed esophageal DNA test that examines individuals DNA molecules for the presence or absence of cytosine methylation; and EsoCheck, a cell collection device that collects cells of targeted region of the esophagus. Lucid Diagnostics Inc. was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.
IPO Year: 2021
Exchange: NASDAQ
Website: luciddx.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/27/2021 | $16.00 | Buy | Ascendiant Capital |
| 12/15/2021 | $17.00 → $13.00 | Buy | Needham |
| 11/8/2021 | $18.00 | Buy | Canaccord Genuity |
| 11/8/2021 | $14.00 | Buy | BTIG Research |
| 11/8/2021 | $21.00 | Overweight | Cantor Fitzgerald |
| 11/8/2021 | $17.00 | Buy | Needham |
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4/A - Lucid Diagnostics Inc. (0001799011) (Issuer)
4 - Lucid Diagnostics Inc. (0001799011) (Issuer)
4 - Lucid Diagnostics Inc. (0001799011) (Issuer)
4 - Lucid Diagnostics Inc. (0001799011) (Issuer)
4 - Lucid Diagnostics Inc. (0001799011) (Issuer)
4 - Lucid Diagnostics Inc. (0001799011) (Issuer)
4 - Lucid Diagnostics Inc. (0001799011) (Issuer)
4 - Lucid Diagnostics Inc. (0001799011) (Issuer)
4 - Lucid Diagnostics Inc. (0001799011) (Issuer)
4 - Lucid Diagnostics Inc. (0001799011) (Issuer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Ascendiant Capital initiated coverage of Lucid Diagnostics with a rating of Buy and set a new price target of $16.00
Needham reiterated coverage of Lucid Diagnostics with a rating of Buy and set a new price target of $13.00 from $17.00 previously
Canaccord Genuity initiated coverage of Lucid Diagnostics with a rating of Buy and set a new price target of $18.00
BTIG Research initiated coverage of Lucid Diagnostics with a rating of Buy and set a new price target of $14.00
Cantor Fitzgerald initiated coverage of Lucid Diagnostics with a rating of Overweight and set a new price target of $21.00
Needham initiated coverage of Lucid Diagnostics with a rating of Buy and set a new price target of $17.00
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4/A - Lucid Diagnostics Inc. (0001799011) (Issuer)
4 - Lucid Diagnostics Inc. (0001799011) (Issuer)
8-K - Lucid Diagnostics Inc. (0001799011) (Filer)
10-Q - Lucid Diagnostics Inc. (0001799011) (Filer)
8-K - Lucid Diagnostics Inc. (0001799011) (Filer)
424B3 - Lucid Diagnostics Inc. (0001799011) (Filer)
EFFECT - Lucid Diagnostics Inc. (0001799011) (Filer)
8-K - Lucid Diagnostics Inc. (0001799011) (Filer)
424B5 - Lucid Diagnostics Inc. (0001799011) (Filer)
S-3 - Lucid Diagnostics Inc. (0001799011) (Filer)
8-K - Lucid Diagnostics Inc. (0001799011) (Filer)
10-Q - Lucid Diagnostics Inc. (0001799011) (Filer)
Fastest customizable press release news feed in the world
Lucid processed 2,756 EsoGuard® 2Q25 tests, recognized revenue of $1.2 million,and secured CAC meeting on Medicare LCD for EsoGuard to be held on September4 Veris Health completed 2Q25 financing, relaunched development of implantablephysiological monitor, and initiated integration steps to launch commercial phase withOSU-The James Conference call and webcast to be held today, August 14, at 8:30 AM EDT NEW YORK, Aug. 14, 2025 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiari
Processed 2,756 EsoGuard® tests and recognized 2Q25 revenue of $1.2 million, ending quarter with over $30 million in proforma cash and extending runway well past upcoming reimbursement milestones Multi-Jurisdictional Contractor Advisory Committee (CAC) meeting on Medicare Local Coverage Determination (LCD) for EsoGuard to be held on September 4 Conference call and webcast to be held today, August 13, at 8:30 AM EDT NEW YORK, Aug. 13, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (NASDAQ:PAVM) ("PAVmed"), today provided a business update for the Company and
NEW YORK, Aug. 5, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced that management will participate in the following upcoming investor conferences: 10th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference 1x1 Meetings: August 11-12, 2025Location: VirtualCanaccord Genuity 45th Annual Growth Conference Fireside Chat: August 13, 2025, at 2:30 PM ETLocation: Boston, MAThe live and archived webcast of the Canacc
Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK, July 31, 2025 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it will host a business update conference call and webcast on Thursday, August 14, 2025, at 8:30 AM ET. During the call, Lishan Aklog, M.D., PAVmed's Chairman and Chief Executive Officer, will provide a business update including an overview of the Company's operations and growth strategy. In addition, Dennis McGrath, PAVmed's President and Chief Financial Officer, will discuss the Company's secon
Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK, July 30, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced that it will host a business update conference call and webcast on Wednesday, August 13, 2025, at 8:30 AM ET. During the call, Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, will provide a business update, including an overview of the Company's operations and continued growth strategy. In addition, Dennis McGrath, Lucid's Chief Financial Officer, will discuss the Company's second quarter 2025 fi
NEW YORK, July 30, 2025 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it had received written notification from the Listing Qualifications Department of the Nasdaq Stock Market LLC ("Nasdaq") that the Company was eligible for a 180-day extension to regain compliance with the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the "Rule"). The Company now has until January 19, 2026 to meet the requirement.
Virtual public CAC meeting to be held September 4, 2025, at 2:00 p.m. ET NEW YORK, July 16, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced that on Thursday, September 4, 2025, from 2:00 to 4:00 p.m. ET, MolDX-participating Medicare Administrative Contractors (MACs)—Palmetto GBA, CGS Administrators, Noridian Healthcare Solutions, and WPS Government Health Administrators—will convene a MolDX Contractor Advisory Committee (CAC) Meeting of medical experts as a critical step in the reconsideration of Local Coverage Determination (LC
Lucid to partner with Hoag in its mission to eradicate esophageal cancer by expanding access to EsoGuard precancer testing across its extensive healthcare delivery network NEW YORK, June 18, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced that Hoag, a nationally-recognized regional healthcare delivery network, has launched a comprehensive, integrated esophageal precancer testing program using Lucid Diagnostics' EsoGuard® Esophageal DNA Test. Lucid will partner with Hoag to offer EsoGuard testing across its digestive health, prim
NEW YORK, May 27, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced that the Company will join the small-cap Russell 2000® Index and the broad-market Russell 3000® Index, effective after the close of U.S. equity markets on June 27, 2025, as part of their 2025 annual reconstitution, according to a preliminary list of additions posted by FTSE Russell on May 23, 2025. "We are pleased that Lucid is joining these importa
Lucid secured capital to extend runway well past key upcoming reimbursement milestones; ended 1Q25 with over $40 million in proforma cash Veris Health completed 1Q25 financing, resumed development of implantable physiological monitor, and will soon launch first commercial partnership with major cancer center PAVmed seeking to leverage infrastructure and expand into biopharma sector; actively evaluating clinical and late preclinical stage assets Conference call and webcast to be held today, May 15th, at 8:30 AM EDT NEW YORK, May 15, 2025 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical
Live Leadership Updates
NEW YORK, May 27, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced that the Company will join the small-cap Russell 2000® Index and the broad-market Russell 3000® Index, effective after the close of U.S. equity markets on June 27, 2025, as part of their 2025 annual reconstitution, according to a preliminary list of additions posted by FTSE Russell on May 23, 2025. "We are pleased that Lucid is joining these importa
Efforts include appointment of seasoned biotech investor Sundeep Agrawal, M.D. to board to replace departing directors NEW YORK, Sept. 16, 2024 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM) ("PAVmed" or the "Company") a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that, as part of its efforts to regain compliance with Nasdaq's listing requirements, Lucid Diagnostics (NASDAQ:LUCD) ("Lucid") will be deconsolidated from PAVmed's financial statements. As a result, PAVmed will no longer report consolidated financials reflecting Lucid's operating losses. PAVmed's holdings of Lucid common stock remain
Final closing yields total gross proceeds of $29.8 million from offering Mr. Matheis serves as President and CEO of Sentara Health, one of the largest not-for-profit integrated health systems in the U.S., which encompasses hospitals, a physician group, and an affiliated health plan NEW YORK, May 7, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced the Company has closed a Series B-1 Preferred Stock offering led by one of the Company's long-time institutional investors, with gross proceeds of $11.6 million, bringing
Manning Brings Vast Digital Health Experience Focused on Demonstrable Growth and Commercial Excellence NEW YORK, April 25, 2023 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM, PAVMZ))) ("PAVmed"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, and its majority-owned digital health subsidiary Veris Health Inc. ("Veris"), today announced the appointment of Gary Manning to the newly created position of President, Veris Health. Mr. Manning reports directly to Lishan Aklog, M.D., PAVmed's Chairman & Chief Executive Officer and Veris' Executive Chairman.
PAVmed Inc. (NASDAQ:PAVM, PAVMZ))) (the "Company" or "PAVmed"), a diversified commercial-stage medical technology company and parent of cancer prevention company Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid"), today announced the appointment of Shaun O'Neil to serve as Executive Vice President and Chief Operating Officer, overseeing diverse corporate operations and commercial activities across the Company and its subsidiaries. Mr. O'Neil has served as PAVmed's Chief Commercial Officer and Executive Vice President, Business Development since joining the Company in 2018. He will serve on the Company's Executive Committee and as an executive officer pursuant to Section 16(a) of the Securities
PAVmed Inc. (NASDAQ:PAVM, PAVMZ))) (the "Company" or "PAVmed"), a diversified commercial-stage medical technology company and parent of cancer prevention company Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid"), today announced the appointment of prominent healthcare services industry leader and president of Care Solutions for Evernorth, Joan Harvey, to its Board of Directors. Ms. Harvey will serve as a member of the Company's Audit and Compensation Committees. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220215005417/en/PAVmed appoints Joan Harvey to its Board of Directors. (Photo: Business Wire) "Ms. Harvey brings a wealth of h
Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid") a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (NASDAQ:PAVM, PAVMZ))) ("PAVmed"), today announced the appointment of highly accomplished molecular biologist Suman M. Verma, M.D., Ph.D. as Lucid's Chief Scientific Officer and PAVmed's VP, Molecular Diagnostics. "I am very pleased to welcome Dr. Verma to the Lucid Diagnostics team," said Lishan Aklog M.D., Lucid's Chairman and Chief Executive Officer. "In her role as VP of Genomic Services at our CLIA laboratory partner, ResearchDx, Dr. Verma played a central role in transferring the EsoGuard® Esophageal DNA Test from the Case Western Reserve Uni
Live finance-specific insights
Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK, July 31, 2025 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it will host a business update conference call and webcast on Thursday, August 14, 2025, at 8:30 AM ET. During the call, Lishan Aklog, M.D., PAVmed's Chairman and Chief Executive Officer, will provide a business update including an overview of the Company's operations and growth strategy. In addition, Dennis McGrath, PAVmed's President and Chief Financial Officer, will discuss the Company's secon
Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK, July 30, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced that it will host a business update conference call and webcast on Wednesday, August 13, 2025, at 8:30 AM ET. During the call, Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, will provide a business update, including an overview of the Company's operations and continued growth strategy. In addition, Dennis McGrath, Lucid's Chief Financial Officer, will discuss the Company's second quarter 2025 fi
Lucid secured capital to extend runway well past key upcoming reimbursement milestones; ended 1Q25 with over $40 million in proforma cash Veris Health completed 1Q25 financing, resumed development of implantable physiological monitor, and will soon launch first commercial partnership with major cancer center PAVmed seeking to leverage infrastructure and expand into biopharma sector; actively evaluating clinical and late preclinical stage assets Conference call and webcast to be held today, May 15th, at 8:30 AM EDT NEW YORK, May 15, 2025 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical
Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK, May 1, 2025 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM, PAVMZ), PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it will host a business update conference call and webcast on Thursday, May 15, 2025, at 8:30 AM ET. During the call, Lishan Aklog, M.D., PAVmed's Chairman and Chief Executive Officer, will provide a business update including an overview of the Company's operations and growth strategy. In addition, Dennis McGrath, PAVmed's President and Chief Financial Officer, will discuss the Compa
Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK, April 30, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced that it will host a business update conference call and webcast on Wednesday, May 14, 2025, at 8:30 AM ET. During the call, Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, will provide a business update, including an overview of the Company's operations and continued growth strategy. In addition, Dennis McGrath, Lucid's Chief Financial Officer, will discuss the Company's first quarter 2025 finan
Lucid processed record test volume, saw rapid initial uptake in concierge medicine contracts, and secured first commercial insurance coverage policies Veris Health secured financing to resume advancement of implantable physiological monitor through FDA clearance and commercial launch PAVmed completed debt restructuring and Lucid deconsolidation to regain Nasdaq compliance and strengthen balance sheet Conference call and webcast to be held today, March 25th, at 8:30 AM EDT NEW YORK, March 25, 2025 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM, PAVMZ)) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital
Processed a record 4,042 EsoGuard tests in 4Q24, a 45% sequential and 84% annual increase Recognized EsoGuard revenue of $1.2 million in 4Q24 New sales channel generated over 20 new cash-pay concierge medicine contracts Secured first agreement to pay for EsoGuard under state biomarker legislation Conference call and webcast to be held today, March 24th at 8:30 AM EDT NEW YORK, March 24, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (NASDAQ:PAVM, PAVMZ)) ("PAVmed"), today provided a business update for the Company and reported financial results for the four
Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK, March 11, 2025 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM, PAVMZ), PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it will host a business update conference call and webcast on Tuesday, March 25, 2025, at 8:30 AM ET. During the call, Lishan Aklog, M.D., PAVmed's Chairman and Chief Executive Officer, will provide a business update including an overview of the Company's operations and growth strategy. In addition, Dennis McGrath, PAVmed's President and Chief Financial Officer, will discuss the C
Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK, March 10, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced that it will host a business update conference call and webcast on Monday, March 24, 2025, at 8:30 AM ET. During the call, Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, will provide a business update, including an overview of the Company's operations and continued growth strategy. In addition, Dennis McGrath, Lucid's Chief Financial Officer, will discuss the Company's fourth quarter 2024 finan
Lucid reports record quarterly EsoGuard® revenue and completes clinical evidence package for imminent submission to formally seek Medicare coverage Veris Health completes pilot program with The Ohio State's James Cancer Hospital and continues pursuit of financing to relaunch development of implantable monitor Ongoing initiatives position PAVmed to preserve Nasdaq listing Conference call and webcast to be held today, November 14th at 8:30 AM EST NEW YORK, Nov. 14, 2024 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM, PAVMZ)) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today provide
This live feed shows all institutional transactions in real time.
SC 13D/A - Lucid Diagnostics Inc. (0001799011) (Subject)
SC 13G/A - Lucid Diagnostics Inc. (0001799011) (Subject)
SC 13D/A - Lucid Diagnostics Inc. (0001799011) (Subject)
SC 13G - Lucid Diagnostics Inc. (0001799011) (Subject)
SC 13D/A - Lucid Diagnostics Inc. (0001799011) (Subject)
SC 13G/A - Lucid Diagnostics Inc. (0001799011) (Subject)
SC 13G - Lucid Diagnostics Inc. (0001799011) (Subject)
SC 13D/A - Lucid Diagnostics Inc. (0001799011) (Subject)
SC 13D - Lucid Diagnostics Inc. (0001799011) (Subject)